

Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com

August 14, 2020

To,
BSE Ltd.
P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 023.
SCRIP CODE: 506767

The National Stock Exchange of India Ltd. Exchange Plaza,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051.

SYMBOL: ALKYLAMINE

Sub.: Outcome of Board Meeting held on August 14, 2020

Dear Sirs,

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the Company held today, the Board of Directors have discussed and inter-alia approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2020. We enclose herewith the Unaudited Financial Results of the Company, along with the Auditors' Limited Review Report thereupon.

The Board Meeting commenced at 11: 30 AM and concluded at $\underline{1:30}$ PM. Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For ALKYL AMINES CHEMICALS LTD.

Chintamani D. Thatte

General Manager (Secretarial) & Company Secretary

& Compliance Officer

Encl.: As above

N. M. RAIJI & CO.

Chartered Accountants
Universal Insurance Building,
Pherozeshah Mehta Road,
Mumbai-400 00 . INDIA

Telephone: 2287 0068

2287 3463

Telefax : 91 (22) 2282 8646 E-mail : nmr.ho@nmraiji.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

The Board of Directors Alkyl Amines Chemicals Limited 401-407, Nirman Vyapar Kendra, Plot No.10, Sector 17, DBC, Vashi, Navi Mumbai - 400703

- 1. We have reviewed the accompanying statement of unaudited financial results of Alkyl Amines Chemicals Limited ("the Company"), for the quarter ended June 30, 2020 ("the Statement"), together with the relevant notes thereon (the "Statement"). This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Discosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") as amended, which has been initialled by us for identification purposes. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
- 3. A review of interim financials is limited primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is disclosed, or that it contains any material misstatement.

RAIJ

MUMBAL

For N. M. Raiji & Co. Chartered Accountants Firm Registration No.:108296W

Vinay D. Balse

Partner

Membership No.: 039434


UDIN: 20039434AAAADT9701

Place: Mumbai

Date: August 14, 2020



Alkyl Amines Chemicals Limited





STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,2020

(Rs.in Lakhs) (Except per share data)

	l	Quarter ended (Except per share dat			
Sr. No		Jun 30, 2020 Mar 31, 2020 Jun 30, 2019			Mar 31, 2020
		Unaudited	Audited	Unaudited	Audited
1.	Revenue from Operations	24,515.21	23,476.51	26,623.05	99,287.76
11.	Other Income	118.06	261.93	133.26	701.16
III.	Total Revenue (I+II)	24,633.27	23,738.44	26,756.31	99,988.92
IV.	Expenses				
	Cost of Materials Consumed	10,793.45	11,054.36	13,649.71	47,621.68
	Changes in Inventories of Finished Goods and Work-in-Progress	19.81	(264.15)	1,061.30	827.78
	Employee benefit costs	1,991.69	1,695.74	1,668.96	6,964.15
- 1	Finance Costs	192.35	189.32	363.32	1,025.39
	Depreciation and Amortisation Expense	701.96	720.25	639.94	2,690.98
	Other Expenses	3,972.11	4,232.32	4,327.63	18,172.17
	Total Expenses (IV)	17,671.37	17,627.84	21,710.86	77,302.15
	Profit before Exceptional Items and Tax (III-IV) Exceptional Items	6,961.90	6,110.60	5,045.45	22,686.77 3,284.16
	Profit before tax (V+VI)	6,961.90	6,110.60	5,045.45	25,970.93
	Tax Expense :	0,001.00	0,110.00	0,010.10	20,070.00
	Current Tax	1,545.96	1,453.14	1,499.11	5,403.55
	Deferred Tax	145.34	(266.74)	37.05	(1,030.04)
	Tax adjustments of earlier years	(7.53)	3.42		69.30
-	Total Tax Expenses	1,683.77	1,189.82	1,536.16	4,442.81
Χ.	Net Profit for the Period/Year (VII-VIII)	5,278.13	4,920.78	3,509.29	21,528.12
	Other Comprehensive Income/ (Expense)				
	a) Items that will not be reclassified to profit or loss Remeasurement gain/(losses) on defined benefit	(79.49)	(13.13)	(65.16)	(171.17)
	b) Income tax relating to items that will not be reclassified to profit or loss	17.59	1.82	19.39	40.38
	c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves	53.52	0.86	-	0.80
	d) Income tax relating to items that may be reclassified to profit or loss	(11.84)	(0.19)	- 1	(0.18)
	Other Comprehensive Income / (Expense) for the period/year (Net of Tax)	(20.22)	(10.64)	(45.77)	(130.17)
a.	Total Comprehensive Income for the period/year	5,257.91	4,910.14	3,463.52	21,397.95
CII.	Paid up Share Capital	1,019.82	1,019.82	1,019.82	1,019.82
(III)	Face Value of Share (Rs)	5.00	5.00	5.00	5.00
1	Earnings Per Equity Share		00000		
1	Basic (Rs)	25.88	24.13	17.21	105.55
	Diluted (Rs)	25.81	24.06	17.16	105.27

Corporate Office: 207 A, Kakad Chambers, 132, Dr. Annie Besant Road Worli, Mumbai - 400 018. INDIA Tel.: 91-22-2493 1385, 6748 8200 • Fax: 91-22-2493 0710 • CIN No : L99999MH1979PLC021796.



Notes:

- The above unaudited financial results have been reviewed and recommended by the Audit Committee at their meeting held on August 14, 2020, and approved by the Board of Directors at their meeting on the same date. The Limited Review, as required under Regulation of the SEBI (Listing Obligations and Disclousre Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the Quarter ended June 30,2020 and they have expressed an unmodified opinion on the same.
- The Company is primarily engaged in the business of "Specialty Chemicals". Accordingly, there are no reportable Segments.
- The Company is continuously monitoring the lockdown situation due to spread of Covid-19 pandemic from mid-March and regularly assesses the impact of pandemic on its business operations and performance. The Company is in the business of manufacture and sale of essential products, being mainly pharmaceutical intermediates and is well positioned to fulfil its existing orders and contracts. The Company has been able to meet all its operational needs and is in a comfortable liquidity position to meet its financial commitments. There is no impact on capital and financial resources of the Company. The assets have not been impacted as a result of the pandemic. The Company continues to abide by the directives and advisories issued by various Government authorities and evaluate the impact of COVID-19 as the situation evolves. While there has not been materially adverse impact of COVID-19 on the Company's business operations so far, it is extremely difficult to assess future impact. The Company expects that the demand for its products from pharmaceuticals sector will continue and, as such, barring unforeseen circumstances there will not be a significant impact of COVID-19 on the operations of the Company.

4 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

FOR ALKYL AMINES CHEMICALS LTD.

YOGESH M Digitally signed by YOGESH M KOTHARI Date: 2020.08.14 12:47:20

YOGESH M.KOTHARI CHAIRMAN & MANAGING DIRECTOR

Place: Mumbai

Date : August 14,2020

